Year archive

Inventiva — 2024 filings

All 89 regulatory filings released by Inventiva (IVA) in 2024, sourced directly from the official regulator.

89 Filings

2024 Period

2024 filings (89)

Filing	Released	Lang
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference Regulatory Filings	2024-12-17	English
Inventiva annonce sa participation à la « 43rd Annual J.P. Morgan Healthcare Conference » Regulatory Filings	2024-12-17	French
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million Share Issue/Capital Change	2024-12-16	English
Inventiva obtient 21,4 millions d'euros complétant la première tranche du financement multi-tranches annoncé précédemment d'un montant maximum de 348 millions d'euros Share Issue/Capital Change	2024-12-16	French
Résultats des votes de l’Assemblée Générale Mixte des actionnaires – 11 décembre 2024 Declaration of Voting Results & Voting Rights Announcements	2024-12-12	French
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-12-12	English
Inventiva publie ses informations financières du 3ème trimestre 2024¹ Earnings Release 9M 2024	2024-11-21	French
Inventiva reports 2024 Third Quarter Financial Information¹ Earnings Release 9M 2024	2024-11-21	English
Information relative au nombre total de droits de vote et d’actions composant le capital social au 4 novembre 2024 Declaration of Voting Results & Voting Rights Announcements	2024-11-20	French
Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024 Regulatory Filings	2024-11-20	English
Assemblée Générale Mixte du 11 décembre 2024 - Modalités de mise à disposition des documents préparatoires AGM Information	2024-11-20	French
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents AGM Information	2024-11-20	English
Inventiva présentera lors de la session « late-breaker » de l'AASLD The Liver Meeting®, les résultats de l'analyse finale de la Phase 2 évaluant la combinaison de lanifibranor avec empagliflozine chez Earnings Release FY 2023	2024-11-15	French
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® lat Regulatory Filings	2024-11-15	English
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH Regulatory Filings	2024-10-30	English
Inventiva annonce la recommandation positive du cinquième DMC de l’étude clinique NATiV3 Phase 3 avec lanifibranor dans la MASH Regulatory Filings	2024-10-30	French
Franchissements de seuils Major Shareholding Notification	2024-10-29	French
Franchissement de seuil Major Shareholding Notification	2024-10-23	French
Franchissement de seuils Major Shareholding Notification	2024-10-23	French
Franchissement de seuils Major Shareholding Notification	2024-10-23	French
Franchissements de seuils Major Shareholding Notification	2024-10-22	French
Franchissement de seuils Major Shareholding Notification	2024-10-21	French
Inventiva annonce un abstract « late breaker » sur l’essai clinique de Phase 2, LEGEND, combinant lanifibranor et empagliflozine, lors du Liver Meeting™ 2024 organisé par l’AASLD Regulatory Filings	2024-10-21	French
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024 Regulatory Filings	2024-10-21	English
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants Capital/Financing Update	2024-10-14	English
Inventiva annonce la mise à disposition d'un prospectus dans le cadre de son financement par l’émission d’actions ordinaires et de bons de souscription d’action préfinancés Capital/Financing Update	2024-10-14	French
Prospectus Capital/Financing Update	2024-10-14	French
Inventiva publie son Rapport Financier Semestriel 2024 – Modalités de mise à disposition ou de consultation Report Publication Announcement	2024-10-14	French
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report Report Publication Announcement	2024-10-14	English
Inventiva annonce un financement allant jusqu’à 348 millions d'euros afin d’avancer l’étude NATiV3 de Phase 3 dans la MASH Capital/Financing Update	2024-10-14	French
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study Capital/Financing Update	2024-10-14	English
RFS 2024 Interim / Quarterly Report H1 2024	2024-10-14	French
Inventiva fait un point sur ses activités et publie ses résultats financiers non audités du premier semestre 2024 Earnings Release H1 2024	2024-09-25	French
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results Interim / Quarterly Report H1 2024	2024-09-25	English
Franchissement de seuil Major Shareholding Notification	2024-08-30	French
Inventiva publie ses informations financières préliminaires du premier semestre 2024¹ Earnings Release H1 2024	2024-07-31	French
Inventiva Reports Preliminary 2024 First-Half Financial Information¹ Earnings Release H1 2024	2024-07-31	English
Inventiva obtient un nouveau brevet au Japon, élargissant la protection de la propriété intellectuelle de lanifibranor Regulatory Filings	2024-07-25	French
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor Regulatory Filings	2024-07-25	English
Franchissement de seuil Major Shareholding Notification	2024-07-23	French
Franchissement de seuil Major Shareholding Notification	2024-07-23	French
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Capital/Financing Update	2024-07-19	French
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Capital/Financing Update	2024-07-19	English
Inventiva annonce l'émission de certificats de royalties pour un montant de 20,1 millions d'euros Capital/Financing Update	2024-07-18	French
Inventiva announces a €20.1 million issuance of royalty certificates Capital/Financing Update	2024-07-18	English
Franchissement de seuil Major Shareholding Notification	2024-07-12	French
Inventiva fait le point sur son programme clinique NATiV3 évaluant lanifibranor dans la MASH/NASH et sur sa situation financièr Regulatory Filings	2024-07-05	French
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position Earnings Release FY 2024	2024-07-05	English
DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS AUTORISE PAR L'ASSEMBLEE GENERALE ORDINAIRE DU 20 JUIN 2024 Transaction in Own Shares	2024-06-21	French
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024 AGM Information	2024-06-21	English
Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunies le 20 juin 2024 Declaration of Voting Results & Voting Rights Announcements	2024-06-21	French
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024 AGM Information	2024-06-21	English
Information relative au nombre total de droits de vote et d’actions composant le capital social au 13 mai 2024 Share Issue/Capital Change	2024-05-30	French
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents Report Publication Announcement	2024-05-30	English
Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-05-30	English
Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposition des documents préparatoires AGM Information	2024-05-30	French
Franchissement de seuil Major Shareholding Notification	2024-05-27	French
Inventiva annonce deux présentations scientifiques lors de l’EASL International Liver Congress™ 2024 Regulatory Filings	2024-05-22	French
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024 Investor Presentation	2024-05-22	English
Inventiva publie ses informations financières du 1 ? ? trimestre 2024¹ et fait un point sur ses activités Earnings Release Q1 2024	2024-05-21	French
Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update Earnings Release Q1 2024	2024-05-21	English
Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASH Regulatory Filings	2024-05-16	French
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH Regulatory Filings	2024-05-16	English
Inventiva annonce la publication dans Nature Communications de résultats complémentaires de l’étude clinique de Phase II NATIVE démontrant l’amélioration de marqueurs de santé cardiométabolique chez l Regulatory Filings	2024-05-13	French
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with Earnings Release FY 2024	2024-05-13	English
Franchissement de seuil Major Shareholding Notification	2024-04-24	French
Franchissement de seuil Major Shareholding Notification	2024-04-23	French
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F Report Publication Announcement FY 2023	2024-04-03	English
DEU 2023 Annual Report (ESEF) FY 2023	2024-04-03	French
DEU 2023 Annual Report (ESEF) FY 2023	2024-04-03	French
Inventiva announces the nomination of Andre Turenne as Director Board/Management Information	2024-03-28	English
Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateur Board/Management Information	2024-03-28	French
Inventiva publie ses résultats annuels 2023 Earnings Release FY 2023	2024-03-27	French
Inventiva reports its 2023 full-year results Earnings Release FY 2023	2024-03-27	English
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results Report Publication Announcement	2024-03-22	English
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023 Report Publication Announcement	2024-03-22	French
Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de t Earnings Release FY 2024	2024-03-18	French
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D Earnings Release FY 2024	2024-03-18	English
Franchissement de seuil Major Shareholding Notification	2024-03-14	French
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D Earnings Release Q1 2024	2024-03-13	English
Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2 Report Publication Announcement	2024-03-13	French
Inventiva annonce la reprise du screening dans l’étude clinique de Phase III, NATiV3, évaluant lanifibranor dans la NASH Legal Proceedings Report	2024-03-07	French
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed Regulatory Filings	2024-03-07	English
Inventiva publie ses informations financières préliminaires pour l’exercice fiscal 2023¹ et fait le point sur son étude clinique NATiV3 Earnings Release FY 2023	2024-02-15	French
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3 Earnings Release FY 2023	2024-02-15	English
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Transaction in Own Shares	2024-01-24	French
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Transaction in Own Shares	2024-01-24	English
Inventiva annonce le tirage de la seconde tranche de 25 millions d'euros dans le cadre de son Contrat de Financement avec la Banque Européenne d'Investissement Capital/Financing Update	2024-01-10	French
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank Capital/Financing Update	2024-01-10	English

Filings by year

2026 41 filings
2025 105 filings
2024 89 filings
2023 65 filings
2022 72 filings
2021 75 filings
2020 77 filings
2019 75 filings
2018 34 filings
2017 51 filings